Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action
Open accessThe DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Abstract
BACKGROUND: The NMDA receptor antagonist ketamine was found to act as a fast-acting antidepressant. The effects of single treatment were reported to persist for days to weeks, even in otherwise treatment-refractory cases. Identification of the mechanisms underlying ketamine's antidepressant action may permit development of novel drugs, with similar clinical properties but lacking psychotomimetic, sedative and other side effects. METHODS: We applied whole-genome microarray profiling to analyze detailed time-course (1, 2, 4 and 8 h) of transcriptome alterations in the striatum and hippocampus following acute administration of ketamine, memantine and phencyclidine in C57BL/6 J mice. The transcriptional effects of ketamine were further analyzed using next-generation sequencing and quantitative PCR. Gene expression alterations induced by the NMDA antagonists were compared to the molecular profiles of psychotropic drugs: antidepressants, antipsychotics, anxiolytics, psychostimulants and opioids. RESULTS: We identified 52 transcripts (e.g. Dusp1, Per1 and Fkbp5) with altered expression (FDR < 1 %) in response to treatment with NMDA receptor antagonists. Functional links that connect expression of the regulated genes to the MAPK, IL-6 and insulin signaling pathways were indicated. Moreover, ketamine-regulated expression of specific gene isoforms was detected (e.g. Tsc22d3, Sgk1 and Hif3a). The comparison with other psychotropic drugs revealed that the molecular effects of ketamine are most similar to memantine and phencyclidine. Clustering based on expression profiles placed the NMDA antagonists among fluoxetine, tianeptine, as well as opioids and ethanol. CONCLUSIONS: The identified patterns of gene expression alteration in the brain provided novel molecular classification of ketamine. The transcriptional profile of ketamine reflects its multi-target pharmacological nature. The results reveal similarities between the effects of ketamine and monoaminergic antidepressants that may explain the mechanisms of its rapid antidepressant action.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures


![Fig. 3 Comparison of ketamine, memantine and PCP to other psychotropic drugs based on gene expression patterns in the mouse striatum. Cluster dendrogram (a), PCA plot (b) and heat map (c) were generated based on expression alterations of the top 50 drug-responsive genes found statistically most significant. The gene expression profiles of ketamine (KET), memantine (MEM) and PCP (PCP) were combined with previously published profiles of 18 psychotropic drugs from diverse pharmacological and therapeutic classes: mianserin (MIA), imipramine (IMI), fluoxetine (FLU), bupropion (BUP), tianeptine (TIA), tranylcypromine (TRA), methamphetamine (MET), cocaine (COC), nicotine (NIC), heroin (HER), morphine (MOR), ethanol (ETO), diazepam (DIA), buspirone (BUS), hydroxizine (HYD), clozapine (CLO), risperidone (RIS) and haloperidol (HAL), with saline (SAL) and naive (NAI) groups as the controls [13]. The genes were selected based on ANOVA results for drug factor (top 50) at a threshold of nominal p < 10−26 (after Bonferroni correction p < 10−21). Hierarchical clustering (a) was performed using the measure of Pearson correlation distance and complete distance linkage methods. The PCA plot (b) displays the pattern of similarity between the selected drugs. The first and second components are shown on x and y axis respectively, while the values of the third component are coded by color and size of the circles as indicated on the legend. A comparison of ketamine to antidepressants (c) was based on the patterns of drug-induced transcriptional alterations in the striatum (at 2 h after the treatment). Drug effects were balanced using modified minimum-maximum normalization, where the maximum was set up as average from the top 10 fold changes for every drug. Colored rectangles represent expression levels of the top 50 drug-regulated genes indicated on the right](https://figures.cochat.ai/paper-figures/92ff7af97f394be4a93e3013b2e94ec1/molecular-profile-of-dissociative-drug-ketamine-in-relation-to-its-rapid-figure-3.jpg)

Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In addition, an altered expression of the HPA axis-modulating components, FKBP51 and SGK1 [137, 138], was observed following ketamine administration [139].”
From The HPA Axis as Target for Depression (2024) · cites this paper as [139]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“In the striatum of mice, a significant increase of approximately 1.5 to 2-fold in the transcriptional levels of SGK1 was observed following acute ketamine treatment”
From Serum/glucocorticoid regulated kinase 1 (SGK1) in neurological disorders: pain or gain (2024) · cites this paper as Ficek et al., 2016
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular Mechanisms of Depression: Perspectives on New Treatment Strategies
Lang, U. E., & Borgwardt, S. (2013) · Cellular Physiology and Biochemistry · doi:10.1159/000350094 · Cited by 8,475
Enrichr: interactive and collaborative HTML5 gene list enrichment analysis tool
Chen, E. Y., Tan, C. M., Kou, Y., Duan, Q., Wang, Z., Meirelles, G. V., Clark, N. R., & Ma’ayan, A. (2013) · BMC Bioinformatics · doi:10.1186/1471-2105-14-128 · Cited by 7,814
Lamb, J., Crawford, E. D., Peck, D., Modell, J. W., Blat, I. C., Wrobel, M. J., Lerner, J., Brunet, J.-P., Subramanian, A., Ross, K. N., et al. (2006) · Science · doi:10.1126/science.1132939 · Cited by 5,257
Antidepressant effects of ketamine in depressed patients
Berman, R. M., Cappiello, A., Anand, A., Oren, D. A., Heninger, G. R., Charney, D. S., & Krystal, J. H. (2000) · Biological Psychiatry · doi:10.1016/s0006-3223(99)00230-9 · Cited by 3,856 · cited 2×
“Due to the almost immediate onset of antidepressant effects ketamine could potentially be particularly useful in acute treatment of depression [1].”
A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression.
Zarate, C. A., Singh, J. B., Carlson, P. J., Brutsche, N. E., Ameli, R., Luckenbaugh, D. A., Charney, D. S., & Manji, H. K. (2006) · Archives of General Psychiatry · doi:10.1001/archpsyc.63.8.856 · Cited by 3,766
mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists
Li, N., Lee, B., Liu, R.-J., Banasr, M., Dwyer, J. M., Iwata, M., Li, X.-Y., Aghajanian, G., & Duman, R. S. (2010) · Science · doi:10.1126/science.1190287 · Cited by 2,881 · cited 3×
“Ketamine has been shown to induce expression of synapse-associated proteins through the rapid activation of mTOR-regulated ERK and Akt signaling pathways [11].”
NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses
Autry, A. E., Adachi, M., Nosyreva, E., Na, E. S., Los, M. F., Cheng, P.-F., Kavalali, E. T., & Monteggia, L. M. (2011) · Nature · doi:10.1038/nature10130 · Cited by 1,926 · cited 1×
“Previous results suggested involvement of molecular mechanisms concerning mTOR, BDNF and eEF2 kinase pathways in ketamine action [11, 31].”
Binder, E. B., Salyakina, D., Lichtner, P., Wochnik, G. M., Ising, M., Pütz, B., Papiol, S., Seaman, S., Lucae, S., Kohli, M. A., et al. (2004) · Nature Genetics · doi:10.1038/ng1479 · Cited by 977 · cited 1×
“The Fkbp5 gene is a prime example, as the gene was connected with sensitivity to rapid effects of treatment with antidepressants [34].”
Binder, E. B. (2009) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2009.05.021 · Cited by 968
Ketamine Pharmacology: An Update ( Pharmacodynamics and Molecular Aspects, Recent Findings )
Mion, G., & Villevieille, T. (2013) · CNS Neuroscience & Therapeutics · doi:10.1111/cns.12099 · Cited by 711 · cited 1×
“Ketamine is a noncompetitive antagonist of the NMDA glutamate receptor, with affinities for other receptors and transporters, including dopamine D2 and opioid receptors as well as monoamine transporters [3–6].”
Cited by
Kohtala, S. (2021) · Pharmacological Reports · doi:10.1007/s43440-021-00232-4 · Cited by 142
Jefsen, O. H., Elfving, B., Wegener, G., & Müller, H. K. (2021) · Journal of Psychopharmacology · doi:10.1177/0269881120959614 · Cited by 127
“, 2000); or (d) transcriptional effects of anti-depressive treatments (Bramham et al., 2008; Conti et al., 2007; Ficek et al., 2016; Jeanneteau et al., 2010, 2018; Svenningsson et al., 2013).”
BackgroundThe HPA Axis as Target for Depression
Menke, A. (2024) · Current Neuropharmacology · doi:10.2174/1570159x21666230811141557 · Cited by 131
“In addition, an altered expression of the HPA axis-modulating components, FKBP51 and SGK1 [137, 138], was observed following ketamine administration [139].”
BackgroundOrozco-Solis, R., Montellier, E., Aguilar-Arnal, L., Sato, S., Vawter, M. P., Bunney, B. G., Bunney, W. E., & Sassone-Corsi, P. (2017) · Biological Psychiatry · doi:10.1016/j.biopsych.2017.02.1176 · Cited by 119
“We collected brain tissue at one time point (ZT 13) to avoid the confounding factor of time-dependent variability (50,51) and centered our analyses on the ACC to decrease regional variability (49).”
Astrocyte regulation of synaptic signaling in psychiatric disorders
Kruyer, A., Kalivas, P. W., & Scofield, M. D. (2022) · Neuropsychopharmacology · doi:10.1038/s41386-022-01338-w · Cited by 88
Metadata
- Authors
- Ficek, J., Zygmunt, M., Piechota, M., Hoinkis, D., Rodriguez Parkitna, J., Przewlocki, R., & Korostynski, M.
- Affiliations
- Maj Institute of Pharmacology (PL)
- Venue
- BMC Genomics
- Published
- 2016-05-17
- Volume
- 17
- Issue
- 1
- Pages
- 362-362
- ISSN
- 1471-2164 (ISSN-L)
- PMC
- PMC4869301
- OpenAlex
- W2407277813
- Cited by
- 42
- References
- 48
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 3 · 2023: 5 · 2022: 5 · 2021: 3 · 2020: 8 · 2019: 4 · 2018: 4 · 2017: 4 · 2016: 1
- FWCI
- 3.51
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- cc-by
- Locations
- BMC Genomics (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- Narodowe Centrum Nauki (2011/03/D/NZ3/01686)
- Narodowe Centrum Badań i Rozwoju (POIG.01.01.02-12-004/09 t.3.1)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- ketamine, NMDA receptor antagonists, memantine, phencyclidine, striatum, hippocampus, gene expression profiling, psychotropic drugs, MAPK signaling, IL-6 signaling, insulin signaling, gene isoforms, TSC22D3, SGK1, HIF-3α, MKP-1, Per1, FKBP5
- MeSH terms
- Anesthetics, Dissociative, Animals, Antidepressive Agents, Corpus Striatum, Gene Expression Regulation, Hippocampus, Ketamine, Ligands, Male, Reproducibility of Results, Cluster Analysis, Receptors, N-Methyl-D-Aspartate, Computational Biology, Gene Expression Profiling, Mice, High-Throughput Nucleotide Sequencing, Transcriptome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. https://app.cochat.ai/papers/10.1186/s12864-016-2713-3
- The paper
- Ficek, J., Zygmunt, M., Piechota, M., Hoinkis, D., Rodriguez Parkitna, J., Przewlocki, R., & Korostynski, M. (2016). Molecular profile of dissociative drug ketamine in relation to its rapid antidepressant action. BMC Genomics. https://doi.org/10.1186/s12864-016-2713-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.